PepWisePepWise
App Store Google Play
Start free

Peptide Encyclopedia / KPV

Encyclopedia

KPV

KPV is a tripeptide of lysine, proline, and valine, the C-terminal fragment of alpha-MSH, reported to calm inflammation by downregulating NF-kB signaling. Most of its evidence comes from animal and lab studies plus anecdotal human use, and it holds no FDA approval. Below you'll find reported dosing, reconstitution, safety, and legal status. Educational only, not medical advice.

Track KPV →Dose tools
CategoryImmune
Regulatory statusNot FDA-approved.

Mechanism

A tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-MSH, reported to have anti-inflammatory effects (proposed downregulation of NF-kB signaling).

Half-life

Uncertain; limited reliable human PK data. Treat as unknown.

Regulatory status

Not FDA-approved. Was on FDA Category 2; per April 2026 reporting slated for removal from Category 2, with PCAC review expected around July 2026 (compounding reconsideration only). Research chemical / gray-market.

Safety

Limited human safety data; reported as generally well tolerated in community use, but side effects poorly characterized and long-term safety unknown.

Evidence

Mostly preclinical/animal anti-inflammatory studies plus anecdotal use; minimal human data.

Track KPV in PepWise

Log every dose and injection site, get the reconstitution and units math automatically, follow your cycle, and record how you feel, then export a provider report. KPV tracker, free to start.

Sources

  1. Dalmasso G, et al. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
  2. Xiao B, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. https://pubmed.ncbi.nlm.nih.gov/28624258/
  3. Dalmasso G, et al. Critical Role of PepT1 in Colitis-Associated Cancer and Therapeutic Benefits of KPV. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. https://pubmed.ncbi.nlm.nih.gov/27458604/
  4. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of alpha-MSH. FASEB J. 1989;3(11):2282-2284. https://pubmed.ncbi.nlm.nih.gov/2550304/
  5. Brzoska T, et al. Alpha-MSH and Related Tripeptides: Antiinflammatory and Protective Effects In Vitro and In Vivo. Endocr Rev. 2008;29(5):581-602. https://pubmed.ncbi.nlm.nih.gov/18612139/
  6. Cutuli M, et al. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239. https://pubmed.ncbi.nlm.nih.gov/10670585/

PepWise is an informational and educational tracking tool, not medical advice and not a medical device. KPV may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.